Arrowhead Pharmaceuticals Inc. (ARWR)

31.19
NASDAQ : Health Technology
Prev Close 29.18
Day Low/High 29.30 / 31.56
52 Wk Low/High 10.41 / 30.73
Avg Volume 1.96M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 2.78B
EPS -0.70
P/E Ratio 63.43
Div & Yield N.A. (N.A)
Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will present at the following upcoming conferences.

Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead

Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Arrowhead Research (ARWR) Marked As A Dead Cat Bounce Stock

Arrowhead Research (ARWR) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Arrowhead Research (ARWR) Stock Spikes on Positive Test Results

Arrowhead Research (ARWR) Stock Spikes on Positive Test Results

Arrowhead Research (ARWR) shares are up over 20% after releasing positive test results from its hepatitis B treatment candidate.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a pre-market mover with heavy volume candidate

Arrowhead Reports Peak Reduction In HBsAg Of Up To 99% (1.9 Log) After A Single Dose With Hepatitis B Candidate ARC-520 In Treatment Naïve Cohort Of Phase 2a Study

Arrowhead Reports Peak Reduction In HBsAg Of Up To 99% (1.9 Log) After A Single Dose With Hepatitis B Candidate ARC-520 In Treatment Naïve Cohort Of Phase 2a Study

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is hosting an analyst day today in New York, with a presentation starting at 11:00 a.

Strong On High Volume: Arrowhead Research (ARWR)

Strong On High Volume: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead Research (ARWR) Stock: Weak On High Volume Today

Arrowhead Research (ARWR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead Research (ARWR) Strong On High Relative Volume Today

Arrowhead Research (ARWR) Strong On High Relative Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has nominated ARC-HIF2 as its first therapeutic candidate delivered using a new...

Arrowhead To Webcast Analyst Day Presentation On Hepatitis B Candidate ARC-520

Arrowhead To Webcast Analyst Day Presentation On Hepatitis B Candidate ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day in New York on September 24, 2015, with a presentation...

Arrowhead Research (ARWR) Stock: Weak On High Volume Today

Arrowhead Research (ARWR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead To Present At Jefferies 2015 Hepatitis B Summit

Arrowhead To Present At Jefferies 2015 Hepatitis B Summit

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.

Arrowhead Reports Fiscal 2015 Third Quarter Financial Results

Arrowhead Reports Fiscal 2015 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2015 third quarter ended June 30, 2015.

Arrowhead Research is Now Oversold (ARWR)

Arrowhead Research is Now Oversold (ARWR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of ARWR December 18th Options Trading

First Week of ARWR December 18th Options Trading

Investors in Arrowhead Research Corp saw new options become available this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 140 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead To Report Fiscal 2015 Third Quarter Financial Results

Arrowhead To Report Fiscal 2015 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2015 third quarter ended June 30,...

Arrowhead Receives Regulatory Clearance For ARC-AAT Phase 1 In The United Kingdom And New Zealand

Arrowhead Receives Regulatory Clearance For ARC-AAT Phase 1 In The United Kingdom And New Zealand

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory permission in the United Kingdom and New Zealand to proceed with...

Arrowhead Initiates Dosing Of ARC-AAT In Patients With Alpha-1 Antitrypsin Deficiency

Arrowhead Initiates Dosing Of ARC-AAT In Patients With Alpha-1 Antitrypsin Deficiency

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it dosed the first patient in Part B of a Phase 1 clinical trial of ARC-AAT.

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead Research (ARWR) Stock Gains as Germany Clears Further HBV Tests

Arrowhead Research (ARWR) Stock Gains as Germany Clears Further HBV Tests

Arrowhead Research (ARWR) shares are rising after the company received regulatory approval in Germany to continue testing its hepatitis B treatment candidate.

Arrowhead Research (ARWR) Is Today's Strong On High Volume Stock

Arrowhead Research (ARWR) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead Receives Regulatory Clearance To Begin Additional Phase 2b Studies Of Hepatitis B Candidate ARC-520

Arrowhead Receives Regulatory Clearance To Begin Additional Phase 2b Studies Of Hepatitis B Candidate ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis...

Commit To Purchase Arrowhead Research Corp At $5, Earn 32% Using Options

Commit To Purchase Arrowhead Research Corp At $5, Earn 32% Using Options

Investors eyeing a purchase of Arrowhead Research Corp shares, but tentative about paying the going market price of $6.65/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $5 strike, which has a bid at the time of this writing of $1.60.

Arrowhead Receives Orphan Drug Designation For ARC-AAT

Arrowhead Receives Orphan Drug Designation For ARC-AAT

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the United States Food and Drug Administration (FDA) has granted ARC-AAT orphan drug...

Arrowhead To Present At Jefferies 2015 Healthcare Conference

Arrowhead To Present At Jefferies 2015 Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead's president and chief executive officer Christopher Anzalone, Ph.

RSI Alert: Arrowhead Research (ARWR) Now Oversold

RSI Alert: Arrowhead Research (ARWR) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Arrowhead Reports Fiscal 2015 Second Quarter Financial Results

Arrowhead Reports Fiscal 2015 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2015 second quarter ended March 31, 2015.

Arrowhead Presents Data On Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic And Thromboembolic Diseases

Arrowhead Presents Data On Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic And Thromboembolic Diseases

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented data at IBC's 17 th Annual TIDES Conference in San Diego on the preclinical development of an...

Arrowhead Completes Dosing Healthy Volunteers And Initiates Transition To Patients In Phase 1 Study Of ARC-AAT

Arrowhead Completes Dosing Healthy Volunteers And Initiates Transition To Patients In Phase 1 Study Of ARC-AAT

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed dosing healthy volunteers and will begin dosing patients in an on-going...

TheStreet Quant Rating: C+ (Hold)